The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Prevention of tumor metastasis formation by anti-variant CD44.
Open accessAbstract
A splice variant of CD44 (CD44v) originally discovered on metastases of a rat pancreatic adenocarcinoma (BSp73ASML) has been shown by transfection to confer metastatic behavior to nonmetastatic tumor cells (Günthert U., M. Hofmann, W. Rudy, S. Reber, M. Zöller, I. Haussmann, S. Matzku, A. Wenzel, H. Ponta, and P. Herrlich. 1991. Cell. 65:13). A monoclonal antibody (mAb), 1.1ASML, to the metastasis-specific domain of the CD44v molecule retards growth of lymph node and lung metastases of the metastatic tumor line BSp73ASML, and can efficiently prevent formation of metastases by the transfected line. The antibody is only effective when given before lymph node colonization. Anti-CD44v does not downregulate the expression of CD44v, and prevention of metastatic growth by anti-CD44v is not due to activation of any kind of immune defense. We suggest that the mAb interferes with proliferation of metastasizing tumor cells in the draining lymph node, most probably by blocking a ligand interaction. The interference with metastatic spread will greatly facilitate the exploration of the function of CD44v and, in particular, may also open new strategies for the therapy of human metastases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using protein A-Sepharose
Ey, P. L., Prowse, S. J., & Jenkin, C. R. (1978) · Immunochemistry · doi:10.1016/0161-5890(78)90070-6 · Cited by 2,685
CD44 is the principal cell surface receptor for hyaluronate
Aruffo, A., Stamenkovic, I., Melnick, M., Underhill, C. B., & Seed, B. (1990) · Cell · doi:10.1016/0092-8674(90)90694-a · Cited by 2,438
A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells
Günthert, U., Hofmann, M., Rudy, W., Reber, S., Zöller, M., Hauβmann, I., Matzku, S., Wenzel, A., Ponta, H., & Herrlich, P. (1991) · Cell · doi:10.1016/0092-8674(91)90403-l · Cited by 1,654
Self-citationStamenkovic, I., Amiot, M., Pesando, J. M., & Seed, B. (1989) · Cell · doi:10.1016/0092-8674(89)90638-7 · Cited by 672
Adhesion molecules controlling lymphocyte migration
Stoolman, L. M. (1989) · Cell · doi:10.1016/0092-8674(89)90620-x · Cited by 633
Miyake, K., Underhill, C. B., Lesley, J., & Kincade, P. W. (1990) · The Journal of experimental medicine · doi:10.1084/jem.172.1.69 · Cited by 618
Stamenkovic, I., Aruffo, A. A., Amiot, M., & Seed, B. (1991) · The EMBO Journal · doi:10.1002/j.1460-2075.1991.tb07955.x · Cited by 573
Goldstein, L. A., Zhou, D. F. H., Picker, L. J., Minty, C. N., Bargatze, R. F., Ding, J. F., & Butcher, E. C. (1989) · Cell · doi:10.1016/0092-8674(89)90639-9 · Cited by 555
Jalkanen, S., Bargatze, R. F., de los Toyos, J., & Butcher, E. C. (1987) · The Journal of cell biology · doi:10.1083/jcb.105.2.983 · Cited by 531
Jalkanen, S. T., Bargatze, R. F., Herron, L. R., & Butcher, E. C. (1986) · European Journal of Immunology · doi:10.1002/eji.1830161003 · Cited by 416
Cited by
Yu, Q., & Stamenkovic, I. (2000) · Genes & Development · doi:10.1101/gad.14.2.163 · Cited by 1,754
CD44: can a cancer-initiating cell profit from an abundantly expressed molecule?
Zöller, M. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3023 · Cited by 1,112
Self-citationCD44 and Its Interaction with Extracellular Matrix
Lesley, J., Hyman, R., & Kincade, P. W. (1993) · Advances in Immunology · doi:10.1016/s0065-2776(08)60537-4 · Cited by 1,059
CD44: Structure, Function and Association with the Malignant Process
(1997) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60101-3 · Cited by 1,016
Receptor-Ligand Interaction Between CD44 and Osteopontin (Eta-1)
Weber, G. F., Ashkar, S., Glimcher, M. J., & Cantor, H. (1996) · Science · doi:10.1126/science.271.5248.509 · Cited by 949
Senbanjo, L. T., & Chellaiah, M. A. (2017) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2017.00018 · Cited by 842
Misra, S., Hascall, V. C., Markwald, R. R., & Ghatak, S. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00201 · Cited by 830
Yu, Q., & Stamenkovic, I. (1999) · Genes & Development · doi:10.1101/gad.13.1.35 · Cited by 713
Goodison, S., Urquidi, V, & Tarin, D. (1999) · Molecular Pathology · doi:10.1136/mp.52.4.189 · Cited by 679
Naor, D., Nedvetzki, S., Golan, I., Melnik, L., & Faitelson, Y. (2002) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408360290795574 · Cited by 557
CD44 is required for two consecutive steps in HGF/c-Met signaling
Orian-Rousseau, V., Chen, L., Sleeman, J. P., Herrlich, P., & Ponta, H. (2002) · Genes & Development · doi:10.1101/gad.242602 · Cited by 518
Self-citationHyaluronan–CD44 interactions as potential targets for cancer therapy
Misra, S., Heldin, P., Hascall, V. C., Karamanos, N. K., Skandalis, S. S., Markwald, R. R., & Ghatak, S. (2011) · The FEBS Journal · doi:10.1111/j.1742-4658.2011.08071.x · Cited by 494
CD44, a therapeutic target for metastasising tumours
Orian-Rousseau, V. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.02.024 · Cited by 474
CD44 in Cancer Progression: Adhesion, Migration and Growth Regulation
Marhaba, R., & Zöller, M. (2004) · Journal of Molecular Histology · doi:10.1023/b:hijo.0000032354.94213.69 · Cited by 438
Self-citationExpression and modulation of CD44 variant isoforms in humans
Mackay, C., Terpe, H., Stauder, R., Marston, W., Stark, H., & Günthert, U. (1994) · The Journal of cell biology · doi:10.1083/jcb.124.1.71 · Cited by 437
Hyaluronate receptors: key players in growth, differentiation, migration and tumor progression
Sherman, L., Sleeman, J., Herrlich, P., & Ponta, H. (1994) · Current Opinion in Cell Biology · doi:10.1016/0955-0674(94)90100-7 · Cited by 432
Self-citationThe normal structure and function of CD44 and its role in neoplasia
Sneath, R. J., & Mangham, D. C. (1998) · Molecular Pathology · doi:10.1136/mp.51.4.191 · Cited by 332
Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis
Battula, V. L., Shi, Y., Evans, K. W., Wang, R.-Y., Spaeth, E. L., Jacamo, R. O., Guerra, R., Sahin, A. A., Marini, F. C., Hortobagyi, G., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59735 · Cited by 302
The metastasis gene osteopontin: a candidate target for cancer therapy
Weber, G. F. (2001) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(01)00037-3 · Cited by 286
Redox regulation in stem-like cancer cells by CD44 variant isoforms
Nagano, O., Okazaki, S., & Saya, H. (2013) · Oncogene · doi:10.1038/onc.2012.638 · Cited by 280
The Regulation of Splice-Site Selection, and Its Role in Human Disease
Cooper, T. A., & Mattox, W. (1997) · The American Journal of Human Genetics · doi:10.1086/514856 · Cited by 278
Understanding the Dual Nature of CD44 in Breast Cancer Progression
Louderbough, J. M. V., & Schroeder, J. A. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-11-0156 · Cited by 273
Choi, K. Y., Saravanakumar, G., Park, J. H., & Park, K. (2012) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2011.10.029 · Cited by 264
Dohadwala, M., Batra, R. K., Luo, J., Lin, Y., Krysan, K., Põld, M., Sharma, S., & Dubinett, S. M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m210707200 · Cited by 260
Metadata
- Authors
- Seiter, S., Arch, R., Reber, S., Komitowski, D., Hofmann, M., Ponta, H., Herrlich, P., Matzku, S., & Zöller, M.
- Venue
- The Journal of experimental medicine
- Publisher
- Rockefeller University Press
- Published
- 1993-02-01
- Volume
- 177
- Issue
- 2
- Pages
- 443-455
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2096737169
- Cited by
- 334
- References
- 32
- FWCI
- 10.06
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.